Deficient repair of cisplatin-DNA adducts identified in human testicular teratoma cell lines established from tumours from untreated patients
- 31 December 1994
- journal article
- Published by Elsevier in European Journal Of Cancer
- Vol. 30 (6) , 832-837
- https://doi.org/10.1016/0959-8049(94)90301-8
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Evidence of differential cisplatin-DNA adduct formation, removal and tolerance of DNA damage in three human lung carcinoma cell linesAnti-Cancer Drugs, 1993
- Cisplatin resistance in human cancersPharmacology & Therapeutics, 1991
- A presumed DNA helicase encoded by ERCC-3 is involved in the human repair disorders xeroderma pigmentosum and Cockayne's syndromeCell, 1990
- A hypothesis regarding the protective role of metallothioneins against the toxicity of DNA interactive anticancer drugsToxicology Letters, 1990
- Treatment of Disseminated Germ-Cell Tumors with Cisplatin, Bleomycin, and either Vinblastine or EtoposideNew England Journal of Medicine, 1987
- Establishment and characterisation of three new human ovarian carcinoma cell lines and initial evaluation of their potential in experimental chemotherapy studiesInternational Journal of Cancer, 1987
- Molecular characterization of the human excision repair gene : cDNA cloning and amino acid homology with the yeast DNA repair geneCell, 1986
- Adducts of the antitumor drug cis-diamminedichloroplatinum(II) with DNA: formation, identification, and quantitationBiochemistry, 1985
- Effects of CIS‐platinum on embryonal carcinoma cell lines in vitroInternational Journal of Cancer, 1984
- Isolation of biologically active ribonucleic acid from sources enriched in ribonucleaseBiochemistry, 1979